ID   DAPK2_HUMAN             Reviewed;         370 AA.
AC   Q9UIK4; E9JGM7; O75892; Q24JS1;
DT   28-NOV-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   12-OCT-2022, entry version 192.
DE   RecName: Full=Death-associated protein kinase 2;
DE            Short=DAP kinase 2;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:10376525, ECO:0000269|PubMed:26047703};
DE   AltName: Full=DAP-kinase-related protein 1;
DE            Short=DRP-1;
GN   Name=DAPK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:BAA88063.1};
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, ACTIVITY REGULATION, TISSUE
RP   SPECIFICITY, MUTAGENESIS OF LYS-52, AND CATALYTIC ACTIVITY.
RC   TISSUE=Skeletal muscle {ECO:0000269|PubMed:10376525};
RX   PubMed=10376525; DOI=10.1038/sj.onc.1202701;
RA   Kawai T., Nomura F., Hoshino K., Copeland N.G., Gilbert D.J., Jenkins N.A.,
RA   Akira S.;
RT   "Death-associated protein kinase 2 is a new calcium/calmodulin-dependent
RT   protein kinase that signals apoptosis through its catalytic activity.";
RL   Oncogene 18:3471-3480(1999).
RN   [2] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION,
RP   HOMODIMERIZATION, AND MUTAGENESIS OF LYS-52.
RC   TISSUE=Kidney {ECO:0000312|EMBL:AAC35001.1};
RX   PubMed=10629061; DOI=10.1128/mcb.20.3.1044-1054.2000;
RA   Inbal B., Shani G., Cohen O., Kissil J.L., Kimchi A.;
RT   "Death-associated protein kinase-related protein 1, a novel
RT   serine/threonine kinase involved in apoptosis.";
RL   Mol. Cell. Biol. 20:1044-1054(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION (ISOFORM 2), TISSUE
RP   SPECIFICITY, AND INTERACTION WITH ATF4 (ISOFORM 2).
RX   PubMed=21408167; DOI=10.1371/journal.pone.0017344;
RA   Shoval Y., Berissi H., Kimchi A., Pietrokovski S.;
RT   "New modularity of DAP-kinases: alternative splicing of the DRP-1 gene
RT   produces a ZIPk-like isoform.";
RL   PLoS ONE 6:E17344-E17344(2011).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6] {ECO:0000305}
RP   FUNCTION, HOMODIMERIZATION, MUTAGENESIS OF LYS-52; SER-299; SER-318;
RP   SER-320; SER-323 AND THR-329, AND PHOSPHORYLATION AT SER-318.
RX   PubMed=11230133; DOI=10.1093/emboj/20.5.1099;
RA   Shani G., Henis-Korenblit S., Jona G., Gileadi O., Eisenstein M., Ziv T.,
RA   Admon A., Kimchi A.;
RT   "Autophosphorylation restrains the apoptotic activity of DRP-1 kinase by
RT   controlling dimerization and calmodulin binding.";
RL   EMBO J. 20:1099-1113(2001).
RN   [7]
RP   REVIEW.
RX   PubMed=12445458; DOI=10.1016/s1570-9639(02)00443-0;
RA   Shohat G., Shani G., Eisenstein M., Kimchi A.;
RT   "The DAP-kinase family of proteins: study of a novel group of calcium-
RT   regulated death-promoting kinases.";
RL   Biochim. Biophys. Acta 1600:45-50(2002).
RN   [8]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11980920; DOI=10.1083/jcb.200109094;
RA   Inbal B., Bialik S., Sabanay I., Shani G., Kimchi A.;
RT   "DAP kinase and DRP-1 mediate membrane blebbing and the formation of
RT   autophagic vesicles during programmed cell death.";
RL   J. Cell Biol. 157:455-468(2002).
RN   [9]
RP   REVIEW ON FUNCTION.
RX   PubMed=16756490; DOI=10.1146/annurev.biochem.75.103004.142615;
RA   Bialik S., Kimchi A.;
RT   "The death-associated protein kinases: structure, function, and beyond.";
RL   Annu. Rev. Biochem. 75:189-210(2006).
RN   [10]
RP   FUNCTION, INDUCTION, AND TISSUE SPECIFICITY.
RX   PubMed=17347302; DOI=10.1189/jlb.0606400;
RA   Rizzi M., Tschan M.P., Britschgi C., Britschgi A., Huegli B., Grob T.J.,
RA   Leupin N., Mueller B.U., Simon H.U., Ziemiecki A., Torbett B.E., Fey M.F.,
RA   Tobler A.;
RT   "The death-associated protein kinase 2 is up-regulated during normal
RT   myeloid differentiation and enhances neutrophil maturation in myeloid
RT   leukemic cells.";
RL   J. Leukoc. Biol. 81:1599-1608(2007).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-349, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   FUNCTION.
RX   PubMed=18957423; DOI=10.1074/jbc.m805612200;
RA   Li H., Ray G., Yoo B.H., Erdogan M., Rosen K.V.;
RT   "Down-regulation of death-associated protein kinase-2 is required for beta-
RT   catenin-induced anoikis resistance of malignant epithelial cells.";
RL   J. Biol. Chem. 284:2012-2022(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-299 AND SER-349, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   FUNCTION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=24163421; DOI=10.1189/jlb.0813462;
RA   Geering B., Stoeckle C., Rozman S., Oberson K., Benarafa C., Simon H.U.;
RT   "DAPK2 positively regulates motility of neutrophils and eosinophils in
RT   response to intermediary chemoattractants.";
RL   J. Leukoc. Biol. 95:293-303(2014).
RN   [15]
RP   INTERACTION WITH 14-3-3 PROTEINS, MUTAGENESIS OF SER-367; SER-368; THR-369
RP   AND SER-370, PHOSPHORYLATION AT THR-369, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=26047703; DOI=10.1016/j.bbrc.2015.05.105;
RA   Yuasa K., Ota R., Matsuda S., Isshiki K., Inoue M., Tsuji A.;
RT   "Suppression of death-associated protein kinase 2 by interaction with 14-3-
RT   3 proteins.";
RL   Biochem. Biophys. Res. Commun. 464:70-75(2015).
RN   [16]
RP   VARIANTS [LARGE SCALE ANALYSIS] TRP-60 AND TRP-271.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Calcium/calmodulin-dependent serine/threonine kinase involved
CC       in multiple cellular signaling pathways that trigger cell survival,
CC       apoptosis, and autophagy. Regulates both type I apoptotic and type II
CC       autophagic cell death signals, depending on the cellular setting. The
CC       former is caspase-dependent, while the latter is caspase-independent
CC       and is characterized by the accumulation of autophagic vesicles. Acts
CC       as a mediator of anoikis and a suppressor of beta-catenin-dependent
CC       anchorage-independent growth of malignant epithelial cells. May play a
CC       role in granulocytic maturation (PubMed:17347302). Regulates
CC       granulocytic motility by controlling cell spreading and polarization
CC       (PubMed:24163421). {ECO:0000269|PubMed:17347302,
CC       ECO:0000269|PubMed:24163421, ECO:0000269|PubMed:26047703}.
CC   -!- FUNCTION: Isoform 2 is not regulated by calmodulin. It can
CC       phosphorylate MYL9. It can induce membrane blebbing and autophagic cell
CC       death.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:10376525, ECO:0000269|PubMed:26047703};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:10376525,
CC         ECO:0000269|PubMed:26047703};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10376525, ECO:0000269|PubMed:10629061,
CC         ECO:0000269|PubMed:11230133};
CC   -!- ACTIVITY REGULATION: Activated by Ca(2+)/calmodulin. Regulated by a
CC       double locking mechanism, involving autophosphorylation at Ser-318,
CC       calmodulin binding, and dimerization. In the inactive state, Ser-318 is
CC       phosphorylated, and the kinase is dimeric. Activation involves:
CC       dephosphorylation at Ser-318, release-of-autoinhibition mechanism where
CC       calmodulin binding induces a conformational change that relieves the
CC       steric block of the active site by the autoinhibitory domain, and
CC       generation of the monomeric active form of the kinase.
CC       {ECO:0000269|PubMed:10376525}.
CC   -!- SUBUNIT: Homodimer in its autoinhibited state. Active as monomer (By
CC       similarity). Isoform 2 but not isoform 1 can interact with ATF4.
CC       Interacts with 14-3-3 proteins YWHAB, YWHAE, YWHAG, YWHAH, YWHAQ, YWHAZ
CC       and SFN; the interaction requires DAPK2 phosphorylation at Thr-369 and
CC       suppresses DAPK2 kinase activity and DAPK2-induced apoptosis
CC       (PubMed:26047703). {ECO:0000250, ECO:0000269|PubMed:26047703}.
CC   -!- INTERACTION:
CC       Q9UIK4; Q7Z6B0-2: CCDC91; NbExp=3; IntAct=EBI-77154, EBI-12012082;
CC       Q9UIK4; Q9UIK4: DAPK2; NbExp=4; IntAct=EBI-77154, EBI-77154;
CC       Q9UIK4; Q8IZU0: FAM9B; NbExp=4; IntAct=EBI-77154, EBI-10175124;
CC       Q9UIK4-2; P18848: ATF4; NbExp=2; IntAct=EBI-9693115, EBI-492498;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cytoplasmic vesicle, autophagosome
CC       lumen.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Alpha;
CC         IsoId=Q9UIK4-1; Sequence=Displayed;
CC       Name=2; Synonyms=Beta;
CC         IsoId=Q9UIK4-2; Sequence=VSP_042057;
CC   -!- TISSUE SPECIFICITY: Expressed in neutrophils and eosinophils
CC       (PubMed:24163421). Isoform 2 is expressed in embryonic stem cells (at
CC       protein level). Isoform 1 is ubiquitously expressed in all tissue types
CC       examined with high levels in heart, lung and skeletal muscle.
CC       {ECO:0000269|PubMed:10376525, ECO:0000269|PubMed:17347302,
CC       ECO:0000269|PubMed:21408167, ECO:0000269|PubMed:24163421}.
CC   -!- INDUCTION: Up-regulated during granulocytic maturation
CC       (PubMed:17347302, PubMed:24163421). {ECO:0000269|PubMed:17347302,
CC       ECO:0000269|PubMed:24163421}.
CC   -!- DOMAIN: The autoinhibitory domain sterically blocks the substrate
CC       peptide-binding site by making both hydrophobic and electrostatic
CC       contacts with the kinase core. {ECO:0000250}.
CC   -!- PTM: Autophosphorylation at Ser-318 inhibits its catalytic activity.
CC       Dephosphorylated at Ser-318 in response to activated Fas and TNF-alpha
CC       receptors. {ECO:0000269|PubMed:11230133}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. DAP kinase subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB018001; BAA88063.1; -; mRNA.
DR   EMBL; AF052941; AAC35001.1; -; mRNA.
DR   EMBL; GU056176; ADD83109.1; -; mRNA.
DR   EMBL; AC015914; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC021541; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC114506; AAI14507.1; -; mRNA.
DR   CCDS; CCDS10188.1; -. [Q9UIK4-1]
DR   CCDS; CCDS86463.1; -. [Q9UIK4-2]
DR   RefSeq; NP_055141.2; NM_014326.3. [Q9UIK4-1]
DR   RefSeq; XP_011519718.1; XM_011521416.2.
DR   PDB; 1WMK; X-ray; 3.60 A; A/B/C/D/E/F/G/H=11-330.
DR   PDB; 1WRZ; X-ray; 2.00 A; B=312-330.
DR   PDB; 1Z9X; X-ray; 3.93 A; A/B/C=11-330.
DR   PDB; 1ZUZ; X-ray; 1.91 A; B=312-330.
DR   PDB; 1ZWS; X-ray; 2.90 A; A/B/C/D/E/F/G/H=11-297.
DR   PDB; 2A27; X-ray; 3.00 A; A/B/C/D/E/F/G/H=11-330.
DR   PDB; 2A2A; X-ray; 1.47 A; A/B/C/D=11-330.
DR   PDB; 2CKE; X-ray; 2.80 A; A/B/C/D=11-330.
DR   PDB; 6PAW; X-ray; 2.95 A; A/B/E/F=12-330.
DR   PDB; 7A6R; X-ray; 2.70 A; E/F/G/L=364-370.
DR   PDB; 7A6Y; X-ray; 2.50 A; J/K/L/M=364-370.
DR   PDBsum; 1WMK; -.
DR   PDBsum; 1WRZ; -.
DR   PDBsum; 1Z9X; -.
DR   PDBsum; 1ZUZ; -.
DR   PDBsum; 1ZWS; -.
DR   PDBsum; 2A27; -.
DR   PDBsum; 2A2A; -.
DR   PDBsum; 2CKE; -.
DR   PDBsum; 6PAW; -.
DR   PDBsum; 7A6R; -.
DR   PDBsum; 7A6Y; -.
DR   AlphaFoldDB; Q9UIK4; -.
DR   SMR; Q9UIK4; -.
DR   BioGRID; 117137; 16.
DR   IntAct; Q9UIK4; 10.
DR   STRING; 9606.ENSP00000261891; -.
DR   BindingDB; Q9UIK4; -.
DR   ChEMBL; CHEMBL3123; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q9UIK4; -.
DR   iPTMnet; Q9UIK4; -.
DR   PhosphoSitePlus; Q9UIK4; -.
DR   BioMuta; DAPK2; -.
DR   DMDM; 38605084; -.
DR   EPD; Q9UIK4; -.
DR   jPOST; Q9UIK4; -.
DR   MassIVE; Q9UIK4; -.
DR   MaxQB; Q9UIK4; -.
DR   PaxDb; Q9UIK4; -.
DR   PeptideAtlas; Q9UIK4; -.
DR   PRIDE; Q9UIK4; -.
DR   ProteomicsDB; 19027; -.
DR   ProteomicsDB; 84537; -. [Q9UIK4-1]
DR   ProteomicsDB; 84538; -. [Q9UIK4-2]
DR   Antibodypedia; 13340; 631 antibodies from 41 providers.
DR   DNASU; 23604; -.
DR   Ensembl; ENST00000261891.7; ENSP00000261891.3; ENSG00000035664.11. [Q9UIK4-1]
DR   Ensembl; ENST00000457488.5; ENSP00000408277.1; ENSG00000035664.11. [Q9UIK4-1]
DR   Ensembl; ENST00000558069.5; ENSP00000453235.1; ENSG00000035664.11. [Q9UIK4-2]
DR   Ensembl; ENST00000612884.4; ENSP00000484390.1; ENSG00000035664.11. [Q9UIK4-2]
DR   GeneID; 23604; -.
DR   KEGG; hsa:23604; -.
DR   MANE-Select; ENST00000457488.6; ENSP00000408277.1; NM_014326.5; NP_055141.2.
DR   UCSC; uc002amr.4; human. [Q9UIK4-1]
DR   CTD; 23604; -.
DR   DisGeNET; 23604; -.
DR   GeneCards; DAPK2; -.
DR   HGNC; HGNC:2675; DAPK2.
DR   HPA; ENSG00000035664; Tissue enhanced (skeletal muscle, thyroid gland).
DR   MIM; 616567; gene.
DR   neXtProt; NX_Q9UIK4; -.
DR   OpenTargets; ENSG00000035664; -.
DR   PharmGKB; PA27143; -.
DR   VEuPathDB; HostDB:ENSG00000035664; -.
DR   eggNOG; KOG0032; Eukaryota.
DR   GeneTree; ENSGT00940000153424; -.
DR   HOGENOM; CLU_000288_63_0_1; -.
DR   InParanoid; Q9UIK4; -.
DR   OMA; NLRNCES; -.
DR   OrthoDB; 813445at2759; -.
DR   PhylomeDB; Q9UIK4; -.
DR   TreeFam; TF314166; -.
DR   PathwayCommons; Q9UIK4; -.
DR   Reactome; R-HSA-418889; Caspase activation via Dependence Receptors in the absence of ligand.
DR   SignaLink; Q9UIK4; -.
DR   SIGNOR; Q9UIK4; -.
DR   BioGRID-ORCS; 23604; 10 hits in 1110 CRISPR screens.
DR   ChiTaRS; DAPK2; human.
DR   EvolutionaryTrace; Q9UIK4; -.
DR   GeneWiki; DAPK2; -.
DR   GenomeRNAi; 23604; -.
DR   Pharos; Q9UIK4; Tchem.
DR   PRO; PR:Q9UIK4; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q9UIK4; protein.
DR   Bgee; ENSG00000035664; Expressed in right lobe of thyroid gland and 178 other tissues.
DR   ExpressionAtlas; Q9UIK4; baseline and differential.
DR   Genevisible; Q9UIK4; HS.
DR   GO; GO:0034423; C:autophagosome lumen; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0043276; P:anoikis; IMP:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:2000424; P:positive regulation of eosinophil chemotaxis; IMP:UniProtKB.
DR   GO; GO:0090023; P:positive regulation of neutrophil chemotaxis; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0010506; P:regulation of autophagy; TAS:UniProtKB.
DR   GO; GO:2001242; P:regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding;
KW   Calmodulin-binding; Cytoplasm; Cytoplasmic vesicle; Kinase;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..370
FT                   /note="Death-associated protein kinase 2"
FT                   /id="PRO_0000085912"
FT   DOMAIN          23..285
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          277..344
FT                   /note="Calmodulin-binding"
FT   REGION          292..301
FT                   /note="Autoinhibitory domain"
FT                   /evidence="ECO:0000250"
FT   REGION          348..370
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        149
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         29..37
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         52
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:10376525, ECO:0000269|PubMed:10629061"
FT   MOD_RES         299
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         318
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11230133"
FT   MOD_RES         349
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         369
FT                   /note="Phosphothreonine; by PKB/AKT1"
FT                   /evidence="ECO:0000269|PubMed:26047703"
FT   VAR_SEQ         287..370
FT                   /note="PVDNQQAMVRRESVVNLENFRKQYVRRRWKLSFSIVSLCNHLTRSLMKKVHL
FT                   RPDEDLRNCESDTEEDIARRKALHPRRRSSTS -> SKGEGRAPEQRKTEPTQLKTKHL
FT                   REYTLKCHSSMPPNNSYVNFERFACVVEDVARVDLGCRALVEAHDTIQDDVEALVSIFN
FT                   EKEAWYREENESARHDLSQLRYEFRKVESLKKLLREDIQATGCSLGSMARKLDHLQAQF
FT                   EILRQELSADLQWIQELVGSFQLESGSSEGLGSTFYQDTSESLSELLSRSCTEEFLAGW
FT                   KL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:21408167"
FT                   /id="VSP_042057"
FT   VARIANT         60
FT                   /note="R -> W (in dbSNP:rs56047843)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040436"
FT   VARIANT         271
FT                   /note="R -> W (in dbSNP:rs34270163)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040437"
FT   MUTAGEN         52
FT                   /note="K->A: Loss of activity, apoptotic function and of
FT                   autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:10376525,
FT                   ECO:0000269|PubMed:10629061, ECO:0000269|PubMed:11230133"
FT   MUTAGEN         299..330
FT                   /note="Missing: Loss of ca(2+)-calmodulin binding, increase
FT                   in activity, loss of autophosphorylation."
FT   MUTAGEN         299
FT                   /note="S->A: No effect on Ca(2+)-calmodulin independent
FT                   phosphorylation or apoptotic activity."
FT                   /evidence="ECO:0000269|PubMed:11230133"
FT   MUTAGEN         318
FT                   /note="S->A: Loss of Ca(2+)-calmodulin independent
FT                   phosphorylation, increase in apoptotic activity."
FT                   /evidence="ECO:0000269|PubMed:11230133"
FT   MUTAGEN         318
FT                   /note="S->D: Abolishes apoptotic activity."
FT                   /evidence="ECO:0000269|PubMed:11230133"
FT   MUTAGEN         320
FT                   /note="S->A: No effect on Ca(2+)-calmodulin independent
FT                   phosphorylation or apoptotic activity."
FT                   /evidence="ECO:0000269|PubMed:11230133"
FT   MUTAGEN         323
FT                   /note="S->A: No effect on Ca(2+)-calmodulin independent
FT                   phosphorylation or apoptotic activity."
FT                   /evidence="ECO:0000269|PubMed:11230133"
FT   MUTAGEN         329
FT                   /note="T->A: No effect on Ca(2+)-calmodulin independent
FT                   phosphorylation or apoptotic activity."
FT                   /evidence="ECO:0000269|PubMed:11230133"
FT   MUTAGEN         367
FT                   /note="S->A: No effect on interaction with YWHAE."
FT                   /evidence="ECO:0000269|PubMed:26047703"
FT   MUTAGEN         368
FT                   /note="S->A: No effect on interaction with YWHAE."
FT                   /evidence="ECO:0000269|PubMed:26047703"
FT   MUTAGEN         369
FT                   /note="T->A: Interaction with YWHAE is reduced."
FT                   /evidence="ECO:0000269|PubMed:26047703"
FT   MUTAGEN         370
FT                   /note="S->A: Interaction with YWHAE is increased."
FT                   /evidence="ECO:0000269|PubMed:26047703"
FT   CONFLICT        241
FT                   /note="A -> S (in Ref. 2; AAC35001)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        253
FT                   /note="Q -> H (in Ref. 2; AAC35001)"
FT                   /evidence="ECO:0000305"
FT   HELIX           19..22
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   STRAND          23..31
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   STRAND          33..42
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   TURN            43..45
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   STRAND          48..56
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   STRAND          58..61
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   STRAND          63..66
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   HELIX           68..80
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   STRAND          89..94
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   STRAND          96..103
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   HELIX           111..116
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   HELIX           123..142
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   STRAND          144..146
FT                   /evidence="ECO:0007829|PDB:1ZWS"
FT   HELIX           152..154
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   STRAND          155..158
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   STRAND          162..164
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   STRAND          167..169
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   HELIX           191..193
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   HELIX           196..199
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   HELIX           207..222
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   HELIX           232..240
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   HELIX           248..251
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   HELIX           256..263
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   TURN            270..272
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   HELIX           276..281
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   TURN            283..285
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   HELIX           290..298
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   HELIX           303..312
FT                   /evidence="ECO:0007829|PDB:2A2A"
FT   HELIX           314..328
FT                   /evidence="ECO:0007829|PDB:1ZUZ"
FT   REGION          Q9UIK4-2:434..451
FT                   /note="Leucine-zipper"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   370 AA;  42898 MW;  035E914BBCD881A2 CRC64;
     MFQASMRSPN MEPFKQQKVE DFYDIGEELG SGQFAIVKKC REKSTGLEYA AKFIKKRQSR
     ASRRGVSREE IEREVSILRQ VLHHNVITLH DVYENRTDVV LILELVSGGE LFDFLAQKES
     LSEEEATSFI KQILDGVNYL HTKKIAHFDL KPENIMLLDK NIPIPHIKLI DFGLAHEIED
     GVEFKNIFGT PEFVAPEIVN YEPLGLEADM WSIGVITYIL LSGASPFLGD TKQETLANIT
     AVSYDFDEEF FSQTSELAKD FIRKLLVKET RKRLTIQEAL RHPWITPVDN QQAMVRRESV
     VNLENFRKQY VRRRWKLSFS IVSLCNHLTR SLMKKVHLRP DEDLRNCESD TEEDIARRKA
     LHPRRRSSTS
//
